{"id":"dapsone-disulone","safety":{"commonSideEffects":[{"rate":null,"effect":"Hemolytic anemia"},{"rate":null,"effect":"Methemoglobinemia"},{"rate":null,"effect":"Nausea and gastrointestinal disturbance"},{"rate":null,"effect":"Rash and photosensitivity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dapsone works primarily as a competitive inhibitor of dihydrofolate reductase in bacteria, disrupting folate metabolism and DNA synthesis. Additionally, it possesses immunosuppressive effects through inhibition of neutrophil chemotaxis and reduction of complement-mediated inflammation, making it useful in both infectious and inflammatory dermatological conditions.","oneSentence":"Dapsone is a sulfone antibiotic that inhibits bacterial dihydrofolate reductase and has immunomodulatory properties including suppression of neutrophil function and complement activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:08:41.147Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Leprosy (Hansen's disease)"},{"name":"Dermatitis herpetiformis"},{"name":"Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment"},{"name":"Acne vulgaris"},{"name":"Bullous pemphigoid"}]},"trialDetails":[{"nctId":"NCT04015375","phase":"PHASE3","title":"Study Comparing Test to Aczone 7.5% and Both to a Placebo Control in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Torrent Pharmaceuticals Limited","startDate":"2019-07-11","conditions":"Acne Vulgaris","enrollment":1150},{"nctId":"NCT01773122","phase":"PHASE1","title":"Safety, Tolerability, and Pharmacokinetics of Dapsone in Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-01-21","conditions":"Acne Vulgaris","enrollment":77},{"nctId":"NCT02627417","phase":"PHASE3","title":"Efficacy and Safety of DAPSone as a Second-line Option in Adult Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2015-12","conditions":"Adult Immune Thrombocytopenia (ITP), Dapsone","enrollment":216},{"nctId":"NCT00964366","phase":"PHASE4","title":"Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications","status":"COMPLETED","sponsor":"Stiefel, a GSK Company","startDate":"2009-07","conditions":"Acne Vulgaris","enrollment":53},{"nctId":"NCT02865005","phase":"PHASE3","title":"Trial of Dapsone 5.0% Gel in the Treatment of Acne Vulgaris","status":"COMPLETED","sponsor":"Seegpharm S.A.","startDate":"2016-02","conditions":"Acne Vulgaris","enrollment":2361},{"nctId":"NCT00141037","phase":"PHASE1, PHASE2","title":"Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-03","conditions":"Kidney Diseases, Kidney Transplantation, Kidney Transplant","enrollment":130},{"nctId":"NCT02032407","phase":"PHASE4","title":"A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-12","conditions":"Acne Vulgaris","enrollment":68},{"nctId":"NCT00393679","phase":"PHASE3","title":"Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2007-07","conditions":"Fever, Malaria","enrollment":4112},{"nctId":"NCT01785836","phase":"PHASE1","title":"An Extension Study to Assess the Safety, Tolerability, Efficacy, and Treatment Adherence of Dapsone in Acne Vulgaris","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2013-03","conditions":"Acne Vulgaris","enrollment":""},{"nctId":"NCT01425320","phase":"PHASE1","title":"Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne","status":"WITHDRAWN","sponsor":"Allergan","startDate":"2013-01","conditions":"Acne Vulgaris","enrollment":""},{"nctId":"NCT01231334","phase":"PHASE4","title":"A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-08","conditions":"Acne Vulgaris","enrollment":286},{"nctId":"NCT01313728","phase":"PHASE4","title":"A Study That Evaluates the Decrease in Irritation When Using Additional Acne Treatment Products","status":"COMPLETED","sponsor":"Bausch Health Americas, Inc.","startDate":"2010-12","conditions":"Acne Vulgaris","enrollment":26},{"nctId":"NCT00343187","phase":"PHASE2","title":"A Phase II Study of ACZONE™ (Dapsone) Gel, 5% As a Treatment For Tarceva® (Erlotinib)Related Rash","status":"TERMINATED","sponsor":"Allergan","startDate":"2006-06","conditions":"Rash, Non-small-Cell Lung Cancer","enrollment":2},{"nctId":"NCT00249782","phase":"PHASE2","title":"A Phase II, Randomized Study of ACZONE™ (Dapsone) Gel, 5% for Papulopustular Rosacea.","status":"COMPLETED","sponsor":"Allergan","startDate":"2005-11","conditions":"Rosacea","enrollment":400}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":20,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["experimental arm"],"phase":"phase_3","status":"active","brandName":"Dapsone (Disulone®)","genericName":"Dapsone (Disulone®)","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dapsone is a sulfone antibiotic that inhibits bacterial dihydrofolate reductase and has immunomodulatory properties including suppression of neutrophil function and complement activation. Used for Leprosy (Hansen's disease), Dermatitis herpetiformis, Pneumocystis jirovecii pneumonia (PCP) prophylaxis and treatment.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}